Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology

David Huang, Steven C. Schallhorn, Alan Sugar, Ayad A. Farjo, Parag A. Majmudar, William B. Trattler, David J. Tanzer

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Objective: To review the published literature for evaluation of the safety and outcomes of phakic intraocular lens (pIOL) implantation for the correction of myopia and myopic astigmatism. Methods: Literature searches of the PubMed and Cochrane Library databases were conducted on October 7, 2007, and July 14, 2008. The PubMed search was limited to the English language; the Cochrane Library was searched without language limitations. The searches retrieved 261 references. Of these, panel members chose 85 papers that they considered to be of high or medium clinical relevance to this assessment. The panel methodologist rated the articles according to the strength of evidence. Results: Two pIOLs have been approved by the US Food and Drug Administration (FDA): one iris-fixated pIOL and one posterior-chamber IOL. In FDA trials of iris-fixated pIOLs, uncorrected visual acuity (UCVA) was ≥20/40 in 84% and ≥20/20 in 31% after 3 years. In FDA trials of posterior-chamber pIOLs, UCVA was ≥20/40 in 81% and ≥20/20 in 41%. Satisfaction with the quality of vision with both types of pIOLs was generally high. Toric anterior- and posterior-chamber pIOLs have shown improved clinical results in European trials compared with spherical pIOLs. Comparative studies showed pIOLs to provide better best spectacle-corrected visual acuity (BSCVA) and refractive predictability and stability compared with LASIK and photorefractive keratectomy and to have a lower risk of retinal detachment compared with refractive lens exchange. Reported complications and long-term safety concerns include endothelial cell loss, cataract formation, secondary glaucoma (pupillary block, pigment dispersion), iris atrophy (pupil ovalization), and traumatic dislocation. Conclusions: Phakic IOL implantation is effective in the correction of myopia and myopic astigmatism. In cases of high myopia of -8 diopters or more, pIOLs may provide a better visual outcome than keratorefractive surgeries and better safety than refractive lens exchange. The short-term rates of complications and loss of BSCVA are acceptable. Comprehensive preoperative evaluation and long-term postoperative follow-up examinations are needed to monitor for and prevent serious complications, and to establish long-term safety. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)2244-2258
Number of pages15
JournalOphthalmology
Volume116
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Phakic Intraocular Lenses
Intraocular Lens Implantation
Myopia
Visual Acuity
Iris
United States Food and Drug Administration
Astigmatism
Disclosure
Safety
PubMed
Libraries
Language
Eye Protective Devices
Capsule Opacification
Photorefractive Keratectomy
Laser In Situ Keratomileusis
Anterior Chamber
Retinal Detachment
Pupil
Glaucoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Huang, D., Schallhorn, S. C., Sugar, A., Farjo, A. A., Majmudar, P. A., Trattler, W. B., & Tanzer, D. J. (2009). Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology. Ophthalmology, 116(11), 2244-2258. https://doi.org/10.1016/j.ophtha.2009.08.018

Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology. / Huang, David; Schallhorn, Steven C.; Sugar, Alan; Farjo, Ayad A.; Majmudar, Parag A.; Trattler, William B.; Tanzer, David J.

In: Ophthalmology, Vol. 116, No. 11, 11.2009, p. 2244-2258.

Research output: Contribution to journalArticle

Huang, D, Schallhorn, SC, Sugar, A, Farjo, AA, Majmudar, PA, Trattler, WB & Tanzer, DJ 2009, 'Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology', Ophthalmology, vol. 116, no. 11, pp. 2244-2258. https://doi.org/10.1016/j.ophtha.2009.08.018
Huang, David ; Schallhorn, Steven C. ; Sugar, Alan ; Farjo, Ayad A. ; Majmudar, Parag A. ; Trattler, William B. ; Tanzer, David J. / Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology. In: Ophthalmology. 2009 ; Vol. 116, No. 11. pp. 2244-2258.
@article{a6dbae5186b44bfa992402f6fca63013,
title = "Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology",
abstract = "Objective: To review the published literature for evaluation of the safety and outcomes of phakic intraocular lens (pIOL) implantation for the correction of myopia and myopic astigmatism. Methods: Literature searches of the PubMed and Cochrane Library databases were conducted on October 7, 2007, and July 14, 2008. The PubMed search was limited to the English language; the Cochrane Library was searched without language limitations. The searches retrieved 261 references. Of these, panel members chose 85 papers that they considered to be of high or medium clinical relevance to this assessment. The panel methodologist rated the articles according to the strength of evidence. Results: Two pIOLs have been approved by the US Food and Drug Administration (FDA): one iris-fixated pIOL and one posterior-chamber IOL. In FDA trials of iris-fixated pIOLs, uncorrected visual acuity (UCVA) was ≥20/40 in 84{\%} and ≥20/20 in 31{\%} after 3 years. In FDA trials of posterior-chamber pIOLs, UCVA was ≥20/40 in 81{\%} and ≥20/20 in 41{\%}. Satisfaction with the quality of vision with both types of pIOLs was generally high. Toric anterior- and posterior-chamber pIOLs have shown improved clinical results in European trials compared with spherical pIOLs. Comparative studies showed pIOLs to provide better best spectacle-corrected visual acuity (BSCVA) and refractive predictability and stability compared with LASIK and photorefractive keratectomy and to have a lower risk of retinal detachment compared with refractive lens exchange. Reported complications and long-term safety concerns include endothelial cell loss, cataract formation, secondary glaucoma (pupillary block, pigment dispersion), iris atrophy (pupil ovalization), and traumatic dislocation. Conclusions: Phakic IOL implantation is effective in the correction of myopia and myopic astigmatism. In cases of high myopia of -8 diopters or more, pIOLs may provide a better visual outcome than keratorefractive surgeries and better safety than refractive lens exchange. The short-term rates of complications and loss of BSCVA are acceptable. Comprehensive preoperative evaluation and long-term postoperative follow-up examinations are needed to monitor for and prevent serious complications, and to establish long-term safety. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "David Huang and Schallhorn, {Steven C.} and Alan Sugar and Farjo, {Ayad A.} and Majmudar, {Parag A.} and Trattler, {William B.} and Tanzer, {David J.}",
year = "2009",
month = "11",
doi = "10.1016/j.ophtha.2009.08.018",
language = "English (US)",
volume = "116",
pages = "2244--2258",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Phakic Intraocular Lens Implantation for the Correction of Myopia. A Report by the American Academy of Ophthalmology

AU - Huang, David

AU - Schallhorn, Steven C.

AU - Sugar, Alan

AU - Farjo, Ayad A.

AU - Majmudar, Parag A.

AU - Trattler, William B.

AU - Tanzer, David J.

PY - 2009/11

Y1 - 2009/11

N2 - Objective: To review the published literature for evaluation of the safety and outcomes of phakic intraocular lens (pIOL) implantation for the correction of myopia and myopic astigmatism. Methods: Literature searches of the PubMed and Cochrane Library databases were conducted on October 7, 2007, and July 14, 2008. The PubMed search was limited to the English language; the Cochrane Library was searched without language limitations. The searches retrieved 261 references. Of these, panel members chose 85 papers that they considered to be of high or medium clinical relevance to this assessment. The panel methodologist rated the articles according to the strength of evidence. Results: Two pIOLs have been approved by the US Food and Drug Administration (FDA): one iris-fixated pIOL and one posterior-chamber IOL. In FDA trials of iris-fixated pIOLs, uncorrected visual acuity (UCVA) was ≥20/40 in 84% and ≥20/20 in 31% after 3 years. In FDA trials of posterior-chamber pIOLs, UCVA was ≥20/40 in 81% and ≥20/20 in 41%. Satisfaction with the quality of vision with both types of pIOLs was generally high. Toric anterior- and posterior-chamber pIOLs have shown improved clinical results in European trials compared with spherical pIOLs. Comparative studies showed pIOLs to provide better best spectacle-corrected visual acuity (BSCVA) and refractive predictability and stability compared with LASIK and photorefractive keratectomy and to have a lower risk of retinal detachment compared with refractive lens exchange. Reported complications and long-term safety concerns include endothelial cell loss, cataract formation, secondary glaucoma (pupillary block, pigment dispersion), iris atrophy (pupil ovalization), and traumatic dislocation. Conclusions: Phakic IOL implantation is effective in the correction of myopia and myopic astigmatism. In cases of high myopia of -8 diopters or more, pIOLs may provide a better visual outcome than keratorefractive surgeries and better safety than refractive lens exchange. The short-term rates of complications and loss of BSCVA are acceptable. Comprehensive preoperative evaluation and long-term postoperative follow-up examinations are needed to monitor for and prevent serious complications, and to establish long-term safety. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Objective: To review the published literature for evaluation of the safety and outcomes of phakic intraocular lens (pIOL) implantation for the correction of myopia and myopic astigmatism. Methods: Literature searches of the PubMed and Cochrane Library databases were conducted on October 7, 2007, and July 14, 2008. The PubMed search was limited to the English language; the Cochrane Library was searched without language limitations. The searches retrieved 261 references. Of these, panel members chose 85 papers that they considered to be of high or medium clinical relevance to this assessment. The panel methodologist rated the articles according to the strength of evidence. Results: Two pIOLs have been approved by the US Food and Drug Administration (FDA): one iris-fixated pIOL and one posterior-chamber IOL. In FDA trials of iris-fixated pIOLs, uncorrected visual acuity (UCVA) was ≥20/40 in 84% and ≥20/20 in 31% after 3 years. In FDA trials of posterior-chamber pIOLs, UCVA was ≥20/40 in 81% and ≥20/20 in 41%. Satisfaction with the quality of vision with both types of pIOLs was generally high. Toric anterior- and posterior-chamber pIOLs have shown improved clinical results in European trials compared with spherical pIOLs. Comparative studies showed pIOLs to provide better best spectacle-corrected visual acuity (BSCVA) and refractive predictability and stability compared with LASIK and photorefractive keratectomy and to have a lower risk of retinal detachment compared with refractive lens exchange. Reported complications and long-term safety concerns include endothelial cell loss, cataract formation, secondary glaucoma (pupillary block, pigment dispersion), iris atrophy (pupil ovalization), and traumatic dislocation. Conclusions: Phakic IOL implantation is effective in the correction of myopia and myopic astigmatism. In cases of high myopia of -8 diopters or more, pIOLs may provide a better visual outcome than keratorefractive surgeries and better safety than refractive lens exchange. The short-term rates of complications and loss of BSCVA are acceptable. Comprehensive preoperative evaluation and long-term postoperative follow-up examinations are needed to monitor for and prevent serious complications, and to establish long-term safety. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=70350453952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350453952&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2009.08.018

DO - 10.1016/j.ophtha.2009.08.018

M3 - Article

C2 - 19883852

AN - SCOPUS:70350453952

VL - 116

SP - 2244

EP - 2258

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -